From the First Department of Internal Medicine, Kobe University School of
Medicine, Kobe, Japan.
Correspondence to Seinosuke Kawashima, MD, First Department of Internal Medicine, Kobe University School of Medicine, 7–5-1, Kusunoki-cho, Chuo-ku, Kobe 650, Japan.
Abstract—The precise regulation of
cell growth in the vascular wall maintains vascular integrity, and its
disruption leads to cardiovascular disorders including
atherosclerosis and restenosis. Vascular
endothelial growth factor (VEGF) is a specific mitogen
for endothelial cells, and endothelin-1 (ET-1) is known
to stimulate the proliferation of smooth muscle cells. The aim of this
study was to explore a potential interaction between VEGF and ET-1 on
each expression in vascular cells. VEGF enhanced preproET-1 mRNA
expression and ET-1 secretion in bovine aortic
endothelial cells (BAECs). Similarly, in rat vascular
smooth muscle cells (VSMCs), ET-1 enhanced VEGF mRNA expression and
stimulated VEGF secretion. ET-1–induced VEGF mRNA expression was
abolished by a selective ETA receptor
antagonist, BQ-485, but not by an ETB-selective
blocker, BQ-788. It was also inhibited by pretreatment with actinomycin
D but not by pretreatment with cycloheximide. Furthermore, the
actinomycin D chase experiment revealed that ET-1 did not alter VEGF
mRNA stability. Coculture of BAECs and VSMCs enhanced both ET-1 and
VEGF gene expression in these cells, and the conditioned media from
BAECs and VSMCs reproduced the augmentation of each gene expression,
which was partially inhibited by BQ-485 or an antibody specific to
VEGF. Our results indicate that VEGF and ET-1 have stimulatory
interactions on each expression, which may play an important role in
concomitant proliferation of endothelial and smooth
muscle cells in the vascular wall.
© 1998 American Heart Association, Inc.
Scientific Contributions
Stimulatory Interaction Between Vascular Endothelial Growth Factor and Endothelin-1 on Each Gene Expression
Key Words: endothelial growth factors • endothelin-1 • gene expression • coculture • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  P. Bhargava VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2009; 297(1): R1 - R5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Shimojo, S. Jesmin, S. Zaedi, T. Otsuki, S. Maeda, N. Yamaguchi, K. Aonuma, Y. Hattori, and T. Miyauchi Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H474 - H481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Gomez, M. J. Moreno, A. Iglesias, P. X. Coral, and A. Hernandez Endothelin 1, its Endothelin Type A Receptor, Connective Tissue Growth Factor, Platelet-Derived Growth Factor, and Adrenomedullin Expression in Lungs of Pulmonary Hypertensive and Nonhypertensive Chickens Poult. Sci., May 1, 2007; 86(5): 909 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jesmin, S. Zaedi, N. Shimojo, M. Iemitsu, K. Masuzawa, N. Yamaguchi, C. N. Mowa, S. Maeda, Y. Hattori, and T. Miyauchi Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1030 - E1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Carpenter, S. Schomberg, and K. R. Stenmark Endothelin-mediated increases in lung VEGF content promote vascular leak in young rats exposed to viral infection and hypoxia Am J Physiol Lung Cell Mol Physiol, December 1, 2005; 289(6): L1075 - L1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rodriguez-Vita, M. Ruiz-Ortega, M. Ruperez, V. Esteban, E. Sanchez-Lopez, J. J. Plaza, and J. Egido Endothelin-1, via ETA Receptor and Independently of Transforming Growth Factor-{beta}, Increases the Connective Tissue Growth Factor in Vascular Smooth Muscle Cells Circ. Res., July 22, 2005; 97(2): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rich and V. V. McLaughlin Endothelin Receptor Blockers in Cardiovascular Disease Circulation, November 4, 2003; 108(18): 2184 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yokota, R. C. Ma, J.-Y. Park, K. Isshiki, K. B. Sotiropoulos, R. K. Rauniyar, K. E. Bornfeldt, and G. L. King Role of Protein Kinase C on the Expression of Platelet-Derived Growth Factor and Endothelin-1 in the Retina of Diabetic Rats and Cultured Retinal Capillary Pericytes Diabetes, March 1, 2003; 52(3): 838 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. SCHULZ, C. HUMMEL, S. HEINEMANN, W. SEEGER, and F. GRIMMINGER Serum Levels of Vascular Endothelial Growth Factor Are Elevated in Patients with Obstructive Sleep Apnea and Severe Nighttime Hypoxia Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 67 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iglarz, J.-S. Silvestre, M. Duriez, D. Henrion, and B. I. Levy Chronic Blockade of Endothelin Receptors Improves Ischemia-Induced Angiogenesis in Rat Hindlimbs Through Activation of Vascular Endothelial Growth Factor-NO Pathway Arterioscler Thromb Vasc Biol, October 1, 2001; 21(10): 1598 - 1603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Salani, G. Taraboletti, L. Rosano, V. Di Castro, P. Borsotti, R. Giavazzi, and A. Bagnato Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo Am. J. Pathol., November 1, 2000; 157(5): 1703 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Isales, B. Sumpio, R. J. Bollag, Q. Zhong, K.-H. Ding, W. Du, J. Rodriguez-Commes, R. Lopez, O. R. Rosales, J. Gasalla-Herraiz, et al. Functional parathyroid hormone receptors are present in an umbilical vein endothelial cell line Am J Physiol Endocrinol Metab, September 1, 2000; 279(3): E654 - E662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Luft, E. Mervaala, D. N. Muller, V. Gross, F. Schmidt, J. K. Park, C. Schmitz, A. Lippoldt, V. Breu, R. Dechend, et al. Hypertension-Induced End-Organ Damage : A New Transgenic Approach to an Old Problem Hypertension, January 1, 1999; 33(1): 212 - 218. [Abstract] [Full Text] [PDF]
|
|